![]() |
|||||
|
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() |
Gene: CXorf21 |
Gene summary for CXORF21 |
![]() |
Gene information | Species | Human | Gene symbol | CXorf21 | Gene ID | 80231 |
Gene name | TLR adaptor interacting with endolysosomal SLC15A4 | |
Gene Alias | CXorf21 | |
Cytomap | Xp21.2 | |
Gene Type | protein-coding | GO ID | GO:0002221 | UniProtAcc | Q9HAI6 |
Top |
Malignant transformation analysis |
![]() |
![]() |
Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
80231 | CXorf21 | HCC1 | Human | Liver | HCC | 2.78e-04 | 8.55e-01 | 0.5336 |
80231 | CXorf21 | HCC2 | Human | Liver | HCC | 1.67e-09 | 8.83e-01 | 0.5341 |
80231 | CXorf21 | HCC5 | Human | Liver | HCC | 1.58e-04 | 4.27e-01 | 0.4932 |
Page: 1 |
![]() |
Tissue | Expression Dynamics | Abbreviation |
Liver | ![]() | HCC: Hepatocellular carcinoma |
NAFLD: Non-alcoholic fatty liver disease |
∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
![]() |
![]() |
Tissue | Disease Stage | Enriched GO biological Processes |
Colorectum | AD | ![]() |
Colorectum | SER | ![]() |
Colorectum | MSS | ![]() |
Colorectum | MSI-H | ![]() |
Colorectum | FAP | ![]() |
∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
Page: 1 2 3 4 5 6 7 8 9 |
![]() |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
Page: 1 |
![]() |
Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
Page: 1 |
Top |
Cell-cell communication analysis |
![]() |
Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
![]() |
TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
![]() |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
CXorf21 | SNV | Missense_Mutation | c.239N>T | p.Arg80Ile | p.R80I | Q9HAI6 | protein_coding | tolerated(0.08) | benign(0.299) | TCGA-21-5784-01 | Lung | lung squamous cell carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | |
CXorf21 | SNV | Missense_Mutation | novel | c.710C>T | p.Thr237Ile | p.T237I | Q9HAI6 | protein_coding | tolerated(0.05) | benign(0.037) | TCGA-43-2576-01 | Lung | lung squamous cell carcinoma | Female | <65 | III/IV | Chemotherapy | cisplatin | SD |
CXorf21 | SNV | Missense_Mutation | c.827N>C | p.Leu276Ser | p.L276S | Q9HAI6 | protein_coding | deleterious(0) | probably_damaging(0.993) | TCGA-66-2727-01 | Lung | lung squamous cell carcinoma | Female | <65 | I/II | Unknown | Unknown | SD | |
CXorf21 | SNV | Missense_Mutation | c.503C>G | p.Ser168Cys | p.S168C | Q9HAI6 | protein_coding | deleterious(0.04) | probably_damaging(0.912) | TCGA-85-6561-01 | Lung | lung squamous cell carcinoma | Male | >=65 | I/II | Chemotherapy | cisplatin | SD | |
CXorf21 | SNV | Missense_Mutation | novel | c.679N>G | p.Met227Val | p.M227V | Q9HAI6 | protein_coding | tolerated(0.07) | possibly_damaging(0.487) | TCGA-85-A4JC-01 | Lung | lung squamous cell carcinoma | Male | >=65 | I/II | Chemotherapy | unknown | PD |
CXorf21 | SNV | Missense_Mutation | novel | c.172T>G | p.Cys58Gly | p.C58G | Q9HAI6 | protein_coding | tolerated(0.06) | possibly_damaging(0.61) | TCGA-LA-A446-01 | Lung | lung squamous cell carcinoma | Male | >=65 | I/II | Unknown | Unknown | SD |
CXorf21 | SNV | Missense_Mutation | novel | c.197N>G | p.Ser66Cys | p.S66C | Q9HAI6 | protein_coding | tolerated(0.06) | possibly_damaging(0.808) | TCGA-CN-4723-01 | Oral cavity | head & neck squamous cell carcinoma | Male | >=65 | I/II | Unknown | Unknown | SD |
CXorf21 | SNV | Missense_Mutation | novel | c.31N>C | p.Glu11Gln | p.E11Q | Q9HAI6 | protein_coding | tolerated(0.16) | benign(0) | TCGA-CN-4740-01 | Oral cavity | head & neck squamous cell carcinoma | Female | >=65 | I/II | Chemotherapy | erbitux | PD |
CXorf21 | SNV | Missense_Mutation | c.475T>A | p.Ser159Thr | p.S159T | Q9HAI6 | protein_coding | tolerated(0.06) | benign(0.403) | TCGA-CV-7435-01 | Oral cavity | head & neck squamous cell carcinoma | Female | <65 | I/II | Unknown | Unknown | SD | |
CXorf21 | SNV | Missense_Mutation | novel | c.605A>G | p.Gln202Arg | p.Q202R | Q9HAI6 | protein_coding | tolerated(0.17) | benign(0.184) | TCGA-CV-A45Z-01 | Oral cavity | head & neck squamous cell carcinoma | Male | >=65 | I/II | Unknown | Unknown | PD |
Page: 1 2 3 4 5 6 |
Top |
Related drugs of malignant transformation related genes |
![]() |
(DGIdb 4.0) |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
Page: 1 |